News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
202,139 Results
Type
Article (18923)
Company Profile (122)
Press Release (183094)
Section
Business (62932)
Career Advice (948)
Deals (10078)
Drug Delivery (42)
Drug Development (25626)
Employer Resources (72)
FDA (2916)
Job Trends (4660)
News (100456)
Policy (6519)
Tag
2024 BioCapital Digital (3)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (584)
Accelerated approval (1)
Adcomms (13)
Allergies (23)
Alliances (17682)
ALS (39)
Alzheimer's disease (495)
Antibody-drug conjugate (ADC) (85)
Approvals (2878)
Artificial intelligence (108)
Autoimmune disease (11)
Automation (4)
Bankruptcy (88)
Best Places to Work (3278)
BIOSECURE Act (18)
Biosimilars (29)
Biotechnology (112)
Bladder cancer (27)
Brain cancer (16)
Breast cancer (89)
Cancer (886)
Cardiovascular disease (70)
Career advice (765)
Career pathing (20)
CAR-T (95)
Cell therapy (272)
Cervical cancer (8)
Clinical research (20479)
Collaboration (438)
Compensation (106)
Complete response letters (13)
COVID-19 (803)
CRISPR (21)
C-suite (142)
Cystic fibrosis (49)
Data (781)
Denatured (5)
Depression (21)
Diabetes (66)
Diagnostics (1316)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (21)
Drug discovery (67)
Drug pricing (25)
Drug shortages (4)
Duchenne muscular dystrophy (40)
Earnings (17641)
Editorial (17)
Employer branding (8)
Employer resources (69)
Events (34140)
Executive appointments (373)
FDA (3242)
Featured Employer (22)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (371)
Gene editing (56)
Generative AI (12)
Gene therapy (185)
GLP-1 (291)
Government (717)
Grass and pollen (1)
Guidances (11)
Healthcare (3064)
Huntington's disease (18)
IgA nephropathy (13)
Immunology and inflammation (67)
Indications (12)
Infectious disease (861)
Inflammatory bowel disease (73)
Inflation Reduction Act (3)
Influenza (21)
Intellectual property (47)
Interviews (139)
IPO (4415)
IRA (13)
Job creations (1522)
Job search strategy (707)
Kidney cancer (6)
Labor market (23)
Layoffs (182)
Leadership (11)
Legal (1333)
Liver cancer (22)
Lung cancer (113)
Lymphoma (62)
Machine learning (2)
Management (23)
Manufacturing (144)
MASH (24)
Medical device (1377)
Medtech (1378)
Mergers & acquisitions (5879)
Metabolic disorders (239)
Multiple sclerosis (36)
NASH (8)
Neurodegenerative disease (52)
Neuropsychiatric disorders (14)
Neuroscience (731)
NextGen: Class of 2025 (1698)
Non-profit (601)
Northern California (967)
Now hiring (17)
Obesity (132)
Opinion (183)
Ovarian cancer (35)
Pain (35)
Pancreatic cancer (28)
Parkinson's disease (52)
Partnered (10)
Patents (81)
Patient recruitment (35)
Peanut (14)
People (23414)
Pharmaceutical (15)
Phase I (7751)
Phase II (9712)
Phase III (5730)
Pipeline (493)
Podcasts (33)
Policy (61)
Postmarket research (349)
Preclinical (3175)
Press Release (61)
Prostate cancer (36)
Psychedelics (18)
Radiopharmaceuticals (102)
Rare diseases (192)
Real estate (2549)
Recruiting (36)
Regulatory (5072)
Reports (20)
Research institute (597)
Resumes & cover letters (152)
RNA editing (3)
RSV (13)
Schizophrenia (24)
Series A (88)
Series B (45)
Service/supplier (7)
Sickle cell disease (24)
Southern California (911)
Special edition (10)
Spinal muscular atrophy (67)
Sponsored (11)
Startups (1841)
State (1)
Stomach cancer (5)
Supply chain (23)
Tariffs (6)
The Weekly (28)
United States (7945)
Vaccines (236)
Venture capitalists (32)
Webinars (9)
Weight loss (94)
Women's health (10)
Worklife (7)
Date
Today (51)
Last 7 days (293)
Last 30 days (1117)
Last 365 days (13269)
2025 (3406)
2024 (13650)
2023 (14532)
2022 (17702)
2021 (18682)
2020 (15018)
2019 (11391)
2018 (8993)
2017 (10024)
2016 (9053)
2015 (10406)
2014 (10276)
2013 (9892)
2012 (6590)
2011 (6985)
2010 (6288)
Location
Africa (331)
Alabama (27)
Alaska (3)
Arizona (50)
Arkansas (2)
Asia (14303)
Australia (2840)
California (2284)
Canada (719)
China (202)
Colorado (42)
Connecticut (93)
Delaware (40)
Europe (32313)
Florida (267)
Georgia (59)
Idaho (18)
Illinois (140)
India (11)
Indiana (110)
Iowa (8)
Japan (58)
Kansas (17)
Kentucky (4)
Louisiana (4)
Maine (6)
Maryland (335)
Massachusetts (1757)
Michigan (77)
Minnesota (127)
Missouri (20)
Montana (8)
Nebraska (4)
Nevada (13)
New Hampshire (10)
New Jersey (602)
New Mexico (12)
New York (564)
North Carolina (373)
North Dakota (5)
Northern California (967)
Ohio (62)
Oklahoma (8)
Oregon (10)
Pennsylvania (448)
Puerto Rico (3)
Rhode Island (8)
South America (417)
South Carolina (2)
South Dakota (1)
Southern California (911)
Tennessee (20)
Texas (263)
Utah (30)
Virginia (16)
Washington D.C. (16)
Washington State (328)
Wisconsin (14)
202,139 Results for "io biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
IO Biotech Reports 2024 Business Highlights
March 5, 2025
·
11 min read
Press Releases
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
February 24, 2025
·
4 min read
Press Releases
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
·
5 min read
Press Releases
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
February 21, 2025
·
4 min read
Press Releases
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
February 4, 2025
·
4 min read
Press Releases
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
January 9, 2025
·
7 min read
Drug Development
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.
April 15, 2024
·
4 min read
Press Releases
IO Biotech Announces Participation in Upcoming Investor Conferences
November 12, 2024
·
3 min read
Pharm Country
IO Biotech to Present at Jefferies Global Healthcare Conference
IO Biotech announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York.
May 23, 2024
·
3 min read
Pharm Country
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
April 9, 2024
·
5 min read
1 of 20,214
Next
